CDCP1 and Autoimmunity: In both CD6−/− mice and CD6-humanized mice treated with UMCD6 (mouse anti-human CD6 mAb), striking reductions in clinical signs of disease, pathogenic Th1/Th17 responses, and inflammatory cell infiltration into the target organs are observed, making the CD6-CD318 axis a novel and exciting regulator of T-cell driven autoimmunity (22).